<PAGE> 1
[ARONEX LETTERHEAD]
Contacts:
Connie Stout Michelle Linn
Director, Corporate Communications Feinstein Kean Healthcare
Aronex Pharmaceuticals, Inc. 617-577-8110
281-367-1666 http://www.fkhealth.com
http://www.aronex-pharm.com
FOR IMMEDIATE RELEASE
ARONEX PHARMACEUTICALS PROVIDES UPDATE AT ROBERTSON STEPHENS MEDICAL CONFERENCE
- ARONEX PHARMACEUTICALS ANNOUNCES EQUITY FINANCING AGREEMENT
WITH ACQUA WELLINGTON -
THE WOODLANDS, TEXAS, NOVEMBER 30, 2000 --- Addressing the Robertson Stephens
Medical Conference in New York, Geoffrey F. Cox, Ph.D., Chairman and CEO of
Aronex Pharmaceuticals (Nasdaq National Market: ARNX), provided an update on the
Company's four advanced-stage products. In addition, the Company announced that
it had recently entered into a definitive agreement with Acqua Wellington North
American Equities Fund Ltd. for an equity financing agreement covering the sale
of up to $24 million of the Company's common stock over the next 28 months.
Sales of common stock in this financing may be made pursuant to an effective
shelf registration previously filed by the Company with the Securities and
Exchange Commission. The total number of shares may be sold in increments over
the life of the agreement, at the Company's discretion, with Aronex
Pharmaceuticals controlling the amount and timing of stock.
Dr. Cox stated, "We are pleased to be working with Acqua Wellington on our
equity financing. This type of financing enables us to continue to fund the
Company while minimizing the dilution to existing shareholders. We feel this is
an important step in the continuing development of the Company."
Aronex Pharmaceuticals, Inc. is a biopharmaceutical company that develops and
commercializes proprietary innovative medicines to treat cancer and infectious
diseases. The Company currently has four products in clinical development, two
of which (ATRAGEN(R) and Nyotran(R)) are in an advanced stage. In July 2000, the
Company submitted an Amendment to its New Drug Application for ATRAGEN(R) for
the treatment of patients with acute promyelocytic leukemia, for whom therapy
with tretinoin is necessary but for whom an intravenous administration is
required. The Amendment is currently being reviewed under a
<PAGE> 2
- more -
Aronex Pharmaceuticals, Inc.
Page Two
six-month Prescription Drug User Fee Act guideline. For more information about
Aronex Pharmaceuticals, please visit the Company's web site at
http://www.aronex-pharm.com.
Aronex Pharmaceuticals Safe Harbor Statement
Any statements that are not historical facts, including statements regarding the
Company's clinical development programs and the expected time of clinical trials
and regulatory filings, contained in this release are forward-looking statements
that involve risks and uncertainties, including but not limited to the Company's
early stage of development, clinical trial results, the uncertainty of
regulatory approvals, history of operating losses, future capital needs and
uncertainty of additional funding, governmental regulation, intellectual
property rights, limited sales and marketing experience, competition and
technological change, and other risks identified in the Company's first
amendment to its Annual Report on Form 10-K/A for the year ended December 31,
1999, as filed with the Securities and Exchange Commission.
###
